IL-23 antagonists commonly used in dermatologic practice include guselkumab, risankizumab and tildrakizumab. All are approved by the FDA for the treatment of moderate-to-severe plaque psoriasis. Besides, their utility in hidradenitis suppurativa, pyoderma gangrenosum and pityriasis rubra pilaris has been elucidated.